Compare Hycroft Mining Holding Corporation Class A Common Stock (HYMC) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hycroft Mining Holding Corporation Class A Common Stock vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Hycroft Mining Holding Corporation Class A Common Stock trades at $16.6 (market cap $1.64B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 6.6× Hycroft Mining Holding Corporation Class A Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Hycroft Mining Holding Corporation Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hycroft Mining Holding Corporation Class A Common Stock for 0 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| HYMC | RDY | |
|---|---|---|
Market Cap | $1.64B | $10.78B |
Volume | 1,750,098 | 2,724,343 |
Sector | Basic Materials | Health |
52-Week High | $55.74 | $15.38 |
52-Week Low | $6.75 | $11.38 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.42B | $10.68B |
Dividend Yield | — | 0.65% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hycroft Mining Holding Corporation Class A Common Stock
Hycroft Mining Holding Corporation is a US mining company that owns and operates the Hycroft Mine, a gold and silver deposit in northern Nevada, producing and selling gold and silver from open-pit mining operations.
Read more on HYMC →About Dr. Reddy's Laboratories Ltd Common Stock
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →
